News Headlines

Display #
Title
FDA Gives Nod to J&J’s Tremfya
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
How AstraZeneca’s Silence Led to a $4 Billion Loss Overnight
Novartis stocks drug cabinet with “Big-3” arthritis blockbusters
Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In Kyprolis Label
Same Condition, Different Costs: Should Patients Pay Different Amounts?
Spread of breast cancer reduced by targeting acid metabolite
FDA Panel Unanimously Endorses Novartis’ CAR-T Leukemia Drug
FDA Advisory Committee votes in favor of Pfizer's MYLOTARG (gemtuzumab ozogamicin) for acute myeloid leukemia
Merck KGaA to Shutter Four Sites, Lay Off 200 Employees
Disorderly Brexit could put patients at risk, drug industry warns
Abbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies
Pfizer Announces FDA Accepts Supplemental New Drug Application for Xeljanz for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
Stryker awarded $248.7 million in patent case against Zimmer
U.S. Senate Republicans unveil new healthcare bill amid deep divisions
What Healthcare Marketers Can Learn from Netflix
Five Key Digital Insights From Digital Pharma West
More evidence that outdoor time may help prevent nearsightedness
Mallinckrodt settles U.S. opioid drug probe for $35 million
Cancer survivors get a taste for kefir after exercise
Shortcut method in drug development
U.S. to crack down on opioid treatment programs: Bloomberg
Korea Approves the World’s First Cell and Gene Therapy for Knee Osteoarthritis
Settlement Reached in U.S. Cialis Patent Litigation
Boosts in R&D Spending Drive Biotech Innovation
Dark hair dye and chemical relaxers linked to breast cancer
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Type 1 diabetes risk linked to intestinal viruses
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
FDA panel to focus on safety of Novartis gene therapy drug